In one paragraphArticle in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors at 4 institutions in 1 country.
Sara Rodríguez-MoraImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, 28220 Madrid, Spain.ORCID 0000-0003-2467-116X Lucía Pérez-LamasHematology and Hemotherapy Service, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0003-2348-1698 Miriam Solera SaineroImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, 28220 Madrid, Spain.
Montserrat TorresImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, 28220 Madrid, Spain.
Clara Sánchez-MenéndezImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, 28220 Madrid, Spain.ORCID 0000-0002-9856-6349 Magdalena CoronaHematology and Hemotherapy Service, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0002-6553-0171 Elena MateosImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, 28220 Madrid, Spain.
Guiomar Casado-FernándezImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, 28220 Madrid, Spain.ORCID 0000-0001-5835-896X José AlcamíBiomedical Research Center Network in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0003-0023-7377 Javier García-PérezBiomedical Research Center Network in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0001-7551-7803 Mayte Pérez-OlmedaBiomedical Research Center Network in Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain.ORCID 0000-0003-4553-5423 María Aranzazú Murciano-AntónFamily Medicine, Centro de Salud Doctor Pedro Laín Entralgo, 28924 Alcorcón, Spain.
Javier López-JiménezHematology and Hemotherapy Service, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0002-2969-3002 Valentín García-GutiérrezHematology and Hemotherapy Service, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain.ORCID 0000-0003-4752-0815 Mayte CoirasImmunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, 28220 Madrid, Spain.ORCID 0000-0001-6464-5770 Instituto de Salud Carlos III · ESInstituto Ramón y Cajal de Investigación Sanitaria · ESUniversidad de Alcalá · ESCentro de Salud Casa del Barco · ES
Funding
Tyrosine Kinase inhibition: The New Front in HIV Cure EffortsR01AI143567 · NIAID · UNIVERSITY OF UTAH · PI COIRAS, MAYTE, PLANELLES, VICENTE · 2019 to 2023
$2.3MCoordinated Research Activities at the National Center of Microbiology COV20_00679Instituto de Salud Carlos III PI21/00877; PI22CIII/00059NIAID NIH HHS R01 AI143567NIH grant R01AI143567Spanish Ministry of Science and Innovation PID2019-110275RB-I00
6 · The paper itselfAbstract
The high morbimortality due to SARS-CoV-2 infection in oncohematological diseases (OHD) and hematopoietic stem cell transplant (HSCT) recipients in the pre-vaccine era has made vaccination a priority in this group. After HSCT, the immune responses against common vaccines such as tetanus, varicella, rubella, and polio may be lost. However, the loss of immunity developed by COVID-19 vaccination after HSCT has not been completely defined. In this study, both humoral and cellular immunity against SARS-CoV-2 were analyzed in 29 individuals with OHD who were vaccinated before receiving allogeneic (
Indexed as
allogeneic transplantationautologous transplantationCOVID-19 vaccinecytotoxic responsehumoral response
Identifiers
PMID37190272
PMCPMC10137176
OpenAlexW4366287727
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390